Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.47 |
| ▸ | CA1 | P00915 | 6/20 | 0.47 |
| ▸ | CA2 | P00918 | 6/20 | 0.47 |
| ▸ | CA9 | Q16790 | 6/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | POLQ | O75417 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30421426 | 0.86 | ALDH1A1 (0.49) | CA12CA1CA2CA9CA4 | |
| SCHEMBL30098984 | 0.85 | CA1 (0.46) | CA12CA1CA2CA9CA4 | |
| SCHEMBL12049701 | 0.83 | CA12 (0.51) | CA12CA1CA2CA9CA4 | |
| SCHEMBL19151185 | 0.82 | ATM (0.53) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL19153903 | 0.80 | SMN1; SMN2 (0.54) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL29655926 | 0.79 | NAMPT (0.48) | CA12CA1CA2CA9SYK | |
| SCHEMBL19116586 | 0.79 | PTPN1 (0.60) | ALDH1A1MEN1KMT2A | |
| SCHEMBL28137892 | 0.78 | CA12 (0.39) | CA12CA1CA2CA9CA4 | |
| SCHEMBL6165235 | 0.77 | CA12 (0.39) | CA12CA1CA2CA9CA4 | |
| SCHEMBL19125803 | 0.76 | PTPN1 (0.45) | CA12CA1CA2CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213062-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2022-07-07 | — | — | US | disclosed |
| US-11339141-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210002252-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-10640485-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190119249-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2019-04-25 | — | — | US | disclosed |
| EP-3416638-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2018-12-26 | — | — | EP | disclosed |
| US-10138219-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170240525-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | disclosed |
| WO-2017143291-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240525-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CA12 3754/4885CA1 2828/4885CA2 3501/4885 |
| US-11339141-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | CA12 3754/4885CA1 2828/4885CA2 3501/4885 |
| US-20220213062-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CA12 3754/4885CA1 2828/4885CA2 3501/4885 |
| US-20190119249-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CA12 3754/4885CA1 2828/4885CA2 3501/4885 |
| US-10640485-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | CA12 3754/4885CA1 2828/4885CA2 3501/4885 |
| US-20210002252-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CA12 3754/4885CA1 2828/4885CA2 3501/4885 |
| US-10138219-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | CA12 3754/4885CA1 2828/4885CA2 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.